Want to see GB:SBTX full AI Analyst Report?
SBTX Stock Chart & Stats
13.25 p
-0.88 p(-5.43%)
At close: 4:00 PM EST
13.25 p
-0.88 p(-5.43%)
Day’s Range― - ―
52-Week Range5.00 p - 23.00 p
Previous CloseN/A
Volume282.34K
Average Volume (3M)673.17K
Market Cap
£27.21M
Enterprise Value28.27M
Total Cash (Recent Filing)£3.12M
Total Debt (Recent Filing)£939.16K
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding259,168,670
10 Day Avg. Volume831,404
30 Day Avg. Volume673,172
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)4.06
Price to Sales (P/S)8.25
P/FCF Ratio-29.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£8.20M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained high revenue growth demonstrates product-market fit and expanding partner adoption of SkinBiotix. Over a multi-month horizon, rising top line can enable scale benefits, support future margin improvement, and increase negotiating leverage with brand partners to secure larger, recurring commercial deals.
Conservative Balance SheetA low leverage profile and healthy equity ratio reduce refinancing and solvency risk, giving management flexibility to fund commercialization or R&D without immediate pressure to cut strategic initiatives. This conservatism preserves optionality while the company works toward cash generation.
Platform + B2B Commercial ModelA platform-based, B2B model leaning on partnerships and ingredient supply limits direct consumer marketing costs, enabling scalable revenue via multiple partners. Licensing and ingredient supply create diversified revenue channels and recurring demand potential if partners succeed with product launches.
Bears Say
Persistent UnprofitabilityDespite top-line momentum, ongoing negative net income and EBIT margins mean the business is not yet self-sustaining. Over several months this constrains reinvestment capacity, depresses return on equity, and necessitates external funding until unit economics and cost structure deliver consistent profitability.
Negative Operating & Free Cash FlowNegative operating and free cash flows limit the company’s ability to internally finance growth, increasing reliance on equity or debt. This elevates dilution or leverage risk and can force prioritization away from longer-term R&D or commercial support if cash generation doesn’t improve within the medium term.
Revenue Concentration On Partner ExecutionHeavy reliance on partner-led commercialization concentrates execution risk: product launch timing, partner distribution, or weak take-up can materially swing revenue. This reduces revenue predictability and margin capture, making sustained growth contingent on external partners’ execution over several months.
SkinBioTherapeutics News
SBTX FAQ
What was SkinBioTherapeutics PLC’s price range in the past 12 months?
SkinBioTherapeutics PLC lowest share price was 5.00 p and its highest was 23.00 p in the past 12 months.
What is SkinBioTherapeutics PLC’s market cap?
SkinBioTherapeutics PLC’s market cap is £27.21M.
When is SkinBioTherapeutics PLC’s upcoming earnings report date?
SkinBioTherapeutics PLC’s upcoming earnings report date is Dec 02, 2026 which is in 132 days.
How were SkinBioTherapeutics PLC’s earnings last quarter?
Currently, no data Available
Is SkinBioTherapeutics PLC overvalued?
According to Wall Street analysts SkinBioTherapeutics PLC’s price is currently Overvalued.
Does SkinBioTherapeutics PLC pay dividends?
SkinBioTherapeutics PLC does not currently pay dividends.
What is SkinBioTherapeutics PLC’s EPS estimate?
SkinBioTherapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SkinBioTherapeutics PLC have?
SkinBioTherapeutics PLC has 259,168,670 shares outstanding.
What happened to SkinBioTherapeutics PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SkinBioTherapeutics PLC?
Currently, no hedge funds are holding shares in GB:SBTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SkinBioTherapeutics PLC
SkinBioTherapeutics Plc is a life sciences enterprise dedicated to enhancing human health through the exploration and development of technologies that harness the power of the human microbiome. The company has developed two primary technological platforms: SkinBiotix: This innovative solution is designed to strengthen the skin's natural barrier, offer protection against infections, and promote the repair of damaged skin. AxisBiotix: Focusing on the intricate link between gut health and skin conditions, this technology aims to mitigate the symptoms experienced by individuals with psoriasis. SkinBioTherapeutics serves a wide range of industries, including cosmetic and pharmaceutical skincare, nutritional supplements, and infection control. The company maintains active collaborations with key partners: Croda Plc; the University of Manchester, for the creation of microbiome formulations that bolster the immune system; and Winclove Probiotics B.V., with whom it's developing a unique probiotic blend derived from specific bacterial species known to influence psoriasis pathways. Originally founded in 2015 as Skinbiotix Ltd, the company adopted its current name, SkinBioTherapeutics plc, in December 2016. Its operations are headquartered in Newcastle upon Tyne, United Kingdom.
Technical Analysis
ImmuPharma
―
OptiBiotix Health
―
Arecor Therapeutics PLC
―
Aptamer Group Plc
―
Ondine Biomedical, Inc.
―